BEIGENE (06160) has applied for clinical trial approval for the new injectable Type 1 anti-cancer drug BGB-B455.

The official website of the China National Medical Products Administration Drug Evaluation Center (CDE) recently announced that the application for clinical trials of BEIGENE's class 1 new drug injection BGB-B455 has been accepted. Public information shows that this is a CLDN6 x CD3 bispecific antibody, which is an immune cell connector layout in the breast/gynecology field for BEIGENE. This is the first time this product has applied for IND in China. Claudin protein is a cell protein that plays an important role in the development and progression of cancer. Due to its superior expression in tumors compared to normal tissues, claudin 6 (CLDN6) is an ideal target tumor antigen. Public information shows that BGB-B455 is a bispecific antibody (BsAbs) that targets CLDN6 on tumor cells and CD3 receptors on T cells. It may provide a more tolerable CLDN6-dependent anti-tumor immune response without excessive systemic toxicity.